vs
南玻集团（CSGS）与Embecta Corp.（EMBC）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是Embecta Corp.的1.2倍（$323.1M vs $261.2M），Embecta Corp.净利率更高（16.9% vs 2.2%，领先14.7%），南玻集团同比增速更快（2.0% vs -0.3%），南玻集团自由现金流更多（$55.8M vs $16.6M），过去两年南玻集团的营收复合增速更高（4.6% vs -4.6%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
CSGS vs EMBC — 直观对比
营收规模更大
CSGS
是对方的1.2倍
$261.2M
营收增速更快
CSGS
高出2.3%
-0.3%
净利率更高
EMBC
高出14.7%
2.2%
自由现金流更多
CSGS
多$39.2M
$16.6M
两年增速更快
CSGS
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $261.2M |
| 净利润 | $7.0M | $44.1M |
| 毛利率 | 50.0% | 61.9% |
| 营业利润率 | 9.0% | 31.9% |
| 净利率 | 2.2% | 16.9% |
| 营收同比 | 2.0% | -0.3% |
| 净利润同比 | -79.7% | — |
| 每股收益（稀释后） | $0.24 | $0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSEMBC
| Q4 25 | $323.1M | $261.2M | ||
| Q3 25 | $303.6M | $264.0M | ||
| Q2 25 | $297.1M | $295.5M | ||
| Q1 25 | $299.5M | $259.0M | ||
| Q4 24 | $316.7M | $261.9M | ||
| Q3 24 | $295.1M | $286.1M | ||
| Q2 24 | $290.3M | $272.5M | ||
| Q1 24 | $295.1M | $287.2M |
净利润CSGSEMBC
| Q4 25 | $7.0M | $44.1M | ||
| Q3 25 | $20.5M | $26.4M | ||
| Q2 25 | $12.3M | $45.5M | ||
| Q1 25 | $16.1M | $23.5M | ||
| Q4 24 | $34.5M | $0 | ||
| Q3 24 | $19.1M | $14.6M | ||
| Q2 24 | $13.8M | $14.7M | ||
| Q1 24 | $19.5M | $28.9M |
毛利率CSGSEMBC
| Q4 25 | 50.0% | 61.9% | ||
| Q3 25 | 48.1% | 60.0% | ||
| Q2 25 | 49.5% | 66.7% | ||
| Q1 25 | 48.4% | 63.4% | ||
| Q4 24 | 51.3% | 60.0% | ||
| Q3 24 | 49.4% | 60.7% | ||
| Q2 24 | 47.3% | 69.8% | ||
| Q1 24 | 46.5% | 64.6% |
营业利润率CSGSEMBC
| Q4 25 | 9.0% | 31.9% | ||
| Q3 25 | 10.0% | 21.4% | ||
| Q2 25 | 10.0% | 31.8% | ||
| Q1 25 | 9.8% | 24.3% | ||
| Q4 24 | 13.4% | 11.0% | ||
| Q3 24 | 10.8% | 9.2% | ||
| Q2 24 | 8.8% | 20.5% | ||
| Q1 24 | 10.8% | 13.6% |
净利率CSGSEMBC
| Q4 25 | 2.2% | 16.9% | ||
| Q3 25 | 6.7% | 10.0% | ||
| Q2 25 | 4.1% | 15.4% | ||
| Q1 25 | 5.4% | 9.1% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 6.5% | 5.1% | ||
| Q2 24 | 4.8% | 5.4% | ||
| Q1 24 | 6.6% | 10.1% |
每股收益（稀释后）CSGSEMBC
| Q4 25 | $0.24 | $0.74 | ||
| Q3 25 | $0.73 | $0.44 | ||
| Q2 25 | $0.44 | $0.78 | ||
| Q1 25 | $0.57 | $0.40 | ||
| Q4 24 | $1.20 | $0.00 | ||
| Q3 24 | $0.67 | $0.24 | ||
| Q2 24 | $0.48 | $0.25 | ||
| Q1 24 | $0.68 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $201.3M |
| 总债务越低越好 | $539.5M | — |
| 股东权益账面价值 | $283.7M | $-613.1M |
| 总资产 | $1.5B | $1.1B |
| 负债/权益比越低杠杆越低 | 1.90× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGSEMBC
| Q4 25 | $180.0M | $201.3M | ||
| Q3 25 | $158.4M | $225.5M | ||
| Q2 25 | $145.9M | $230.6M | ||
| Q1 25 | $136.0M | $209.3M | ||
| Q4 24 | $161.8M | $210.0M | ||
| Q3 24 | $118.4M | $267.5M | ||
| Q2 24 | $110.4M | $275.1M | ||
| Q1 24 | $120.8M | $299.8M |
总债务CSGSEMBC
| Q4 25 | $539.5M | — | ||
| Q3 25 | $538.6M | $1.4B | ||
| Q2 25 | $537.8M | — | ||
| Q1 25 | $537.6M | — | ||
| Q4 24 | $538.5M | — | ||
| Q3 24 | $539.5M | $1.6B | ||
| Q2 24 | $540.5M | — | ||
| Q1 24 | $541.5M | — |
股东权益CSGSEMBC
| Q4 25 | $283.7M | $-613.1M | ||
| Q3 25 | $289.5M | $-650.6M | ||
| Q2 25 | $290.7M | $-669.6M | ||
| Q1 25 | $283.1M | $-736.2M | ||
| Q4 24 | $282.6M | $-768.8M | ||
| Q3 24 | $288.4M | $-738.3M | ||
| Q2 24 | $273.3M | $-763.7M | ||
| Q1 24 | $269.3M | $-769.6M |
总资产CSGSEMBC
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.5B | $1.1B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $1.4B | $1.3B | ||
| Q1 24 | $1.3B | $1.2B |
负债/权益比CSGSEMBC
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.86× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.90× | — | ||
| Q4 24 | 1.91× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 2.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $17.2M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $16.6M |
| 自由现金流率自由现金流/营收 | 17.3% | 6.4% |
| 资本支出强度资本支出/营收 | 1.1% | 0.2% |
| 现金转化率经营现金流/净利润 | 8.46× | 0.39× |
| 过去12个月自由现金流最近4个季度 | $141.4M | $205.8M |
8季度趋势，按日历期对齐
经营现金流CSGSEMBC
| Q4 25 | $59.2M | $17.2M | ||
| Q3 25 | $47.9M | $84.0M | ||
| Q2 25 | $37.3M | $81.2M | ||
| Q1 25 | $11.5M | $31.8M | ||
| Q4 24 | $82.5M | $-5.3M | ||
| Q3 24 | $39.5M | $26.6M | ||
| Q2 24 | $43.1M | $-2.1M | ||
| Q1 24 | $-29.4M | $24.3M |
自由现金流CSGSEMBC
| Q4 25 | $55.8M | $16.6M | ||
| Q3 25 | $43.9M | $76.7M | ||
| Q2 25 | $34.6M | $80.8M | ||
| Q1 25 | $7.1M | $31.7M | ||
| Q4 24 | $76.6M | $-6.8M | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $38.8M | $-11.8M | ||
| Q1 24 | $-34.1M | $20.9M |
自由现金流率CSGSEMBC
| Q4 25 | 17.3% | 6.4% | ||
| Q3 25 | 14.5% | 29.1% | ||
| Q2 25 | 11.6% | 27.3% | ||
| Q1 25 | 2.4% | 12.2% | ||
| Q4 24 | 24.2% | -2.6% | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 13.4% | -4.3% | ||
| Q1 24 | -11.6% | 7.3% |
资本支出强度CSGSEMBC
| Q4 25 | 1.1% | 0.2% | ||
| Q3 25 | 1.3% | 2.8% | ||
| Q2 25 | 0.9% | 0.1% | ||
| Q1 25 | 1.5% | 0.0% | ||
| Q4 24 | 1.9% | 0.6% | ||
| Q3 24 | 2.5% | 0.0% | ||
| Q2 24 | 1.5% | 3.6% | ||
| Q1 24 | 1.6% | 1.2% |
现金转化率CSGSEMBC
| Q4 25 | 8.46× | 0.39× | ||
| Q3 25 | 2.34× | 3.18× | ||
| Q2 25 | 3.04× | 1.78× | ||
| Q1 25 | 0.71× | 1.35× | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | 1.82× | ||
| Q2 24 | 3.12× | -0.14× | ||
| Q1 24 | -1.51× | 0.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
